Somatropin effects on liver fat content in AGHD patients-a single centre non-interventional study

Somatropin effects on liver fat content in AGHD patients-a single centre non-interventional study - GH effects on liver fat content in patients with AGHD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044989

Enrollment

Registered

2021-07-29

Start date

2021-06-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult growth hormone deficiency

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: AGHD patients who are treated in Kitasato university between April 1st, 2010 and March 31st,2023.

Exclusion criteria

Exclusion criteria: 1, Patients before and after surgery or with severe trauma 2, Patients with excessive alcohol intake. Estimated ethanol equivalent based on the patient's self-report; 30 g/day for men, 20g /day or more for women 3, Patients with undeniable complications of other liver diseases, including viral hepatitis, autoimmune hepatitis, and drug-induced hepatitis. 4, Patients with severe hepatic impairment, cirrhosis of the liver of Child-Pugh classification B or C 5, Patients with hepatitis virus infection 6, Patients with an apparent malignant tumor 7, Women who are pregnant or may become pregnant 8, Under 20 years old and over 80 years old 9, Patients with mental retardation or linguistic problems that prevent them from fully understanding the research content

Design outcomes

Primary

Measure	Time frame
Prospective group: Change in Hepatic Fat Fraction measured by IDEAL IQ method of liver MRI at the beginning of the study and after 6 months. Retrospective group: Change in Hepatic Fat Fraction measured by IDEAL IQ of liver MRI at study entry, 6 months, or later.	—

Secondary

Measure	Time frame
1. Change in body weight at the beginning of the study, 6 months later in the prospective group, and 6 months later or later in the retrospective group 2. Change in the liver-related enzyme at study entry and after 6 months in the prospective group and after 6 months or later in the retrospective group. 3. Presence of NAFLD assessed at study entry and after 6 months in the prospective group and after 6 months or later in the retrospective group.	—

Measure

Time frame

1. Change in body weight at the beginning of the study, 6 months later in the prospective group, and 6 months later or later in the retrospective group 2. Change in the liver-related enzyme at study entry and after 6 months in the prospective group and after 6 months or later in the retrospective group. 3. Presence of NAFLD assessed at study entry and after 6 months in the prospective group and after 6 months or later in the retrospective group.

—

Countries

Japan

Contacts

Public ContactTomomi Taguchi

Kitasato University School of Medicine Department of Endocrinology, Metabolism & Diabetes

t.tomo@kitasato-u.ac.jp0427788111

Outcome results